The application of nanotechnology in immune checkpoint blockade for cancer treatment
暂无分享,去创建一个
[1] Koichi Araki,et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.
[2] F. Denizot,et al. A new member of the immunoglobulin superfamily—CTLA-4 , 1987, Nature.
[3] Christopher M. Jackson,et al. Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.
[4] R. Scolyer,et al. Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.
[5] K. Roy,et al. Engineering nanoparticles to overcome barriers to immunotherapy , 2016, Bioengineering & translational medicine.
[6] Zhen Gu,et al. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. , 2016, Nano letters.
[7] Zhen Gu,et al. Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody , 2016, Advanced materials.
[8] T. Okazaki,et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.
[9] D. Littman. Releasing the Brakes on Cancer Immunotherapy , 2015, Cell.
[10] R. Herbst,et al. Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.
[11] Shi Jiao,et al. A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors , 2018, Nature Communications.
[12] Axel Hoos,et al. Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.
[13] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[14] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[15] B. Zhu,et al. T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.
[16] L. Zitvogel,et al. Trial watch: IDO inhibitors in cancer therapy , 2014, Oncoimmunology.
[17] A. Nezos,et al. CD40/CD40L signaling and its implication in health and disease , 2009, BioFactors.
[18] T. Honjo,et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.
[19] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[20] D. Munn,et al. Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.
[21] yang-xin fu,et al. CD47 Blockade Triggers T cell-mediated Destruction of Immunogenic Tumors , 2015, Nature Medicine.
[22] Song Li,et al. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier , 2017, Acta Pharmacologica Sinica.
[23] Zhuang Liu,et al. In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy , 2018, Science Translational Medicine.
[24] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[25] Wenbin Lin,et al. Nanoscale Metal-Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy. , 2018, Journal of the American Chemical Society.
[26] Enzo Di Fabrizio,et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy , 2012, International journal of nanomedicine.
[27] Qian Yang,et al. Immunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanoma , 2014, International journal of nanomedicine.
[28] J. Allison,et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine , 2015, Proceedings of the National Academy of Sciences.
[29] Yi Yan Yang,et al. Ovarian Cancer Immunotherapy Using PD‐L1 siRNA Targeted Delivery from Folic Acid‐Functionalized Polyethylenimine: Strategies to Enhance T Cell Killing , 2015, Advanced healthcare materials.
[30] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[31] S. Berger,et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.
[32] G. Prendergast,et al. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.
[33] Baolan Li,et al. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer , 2015, Scientific Reports.
[34] G. Anderson,et al. Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4 , 2011, Science.
[35] H. Kohrt,et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK , 2015, Proceedings of the National Academy of Sciences.
[36] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[37] R. Coffman,et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells , 2016, Proceedings of the National Academy of Sciences.
[38] Shiladitya Sengupta,et al. Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy. , 2016, ACS nano.
[39] P. O'dwyer,et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. , 2013 .
[40] Zhuang Liu,et al. Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer. , 2017, ACS nano.
[41] C. Melief,et al. Cancer immunology. , 2011, Current opinion in immunology.
[42] Zhaocai Zhou,et al. Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy. , 2016, Nano letters.
[43] S. Son,et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy , 2018, Science Advances.
[44] Conglian Yang,et al. Biomimetic Nanovesicles for Enhanced Antitumor Activity of Combinational Photothermal and Chemotherapy. , 2018, Molecular pharmaceutics.
[45] Ross A Soo,et al. De-novo and acquired resistance to immune checkpoint targeting. , 2017, The Lancet. Oncology.
[46] M. Curran,et al. 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity , 2015, Front. Oncol..
[47] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[48] J. Moffett,et al. Tryptophan and the immune response , 2003, Immunology and cell biology.
[49] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[50] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[51] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[52] Yaping Li,et al. Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment , 2018, Advanced materials.
[53] M. Hemann,et al. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. , 2015, Journal of the American Chemical Society.
[54] W. Hennink,et al. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer. , 2015, Biomaterials.
[55] Jens-Peter Volkmer,et al. Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.
[56] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[58] Shu-Ying Liu,et al. MgAl-layered double hydroxide nanoparticles co-delivering siIDO and Trp2 peptide effectively reduce IDO expression and induce cytotoxic T-lymphocyte responses against melanoma tumor in mice. , 2017, Journal of materials chemistry. B.
[59] A. Korman,et al. Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells , 2013, Cancer Immunology Research.
[60] S. Rosenberg,et al. Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade , 2005, The Journal of Immunology.
[61] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[62] G. Gibney,et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. , 2014 .
[63] R. Govindan,et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] S. Uprichard. The therapeutic potential of RNA interference , 2005, FEBS Letters.
[65] John G. Doench,et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.
[66] L. Martiny,et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.
[67] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.
[68] Napoleone Ferrara,et al. Ten years of anti-vascular endothelial growth factor therapy , 2016, Nature Reviews Drug Discovery.
[69] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[70] Huan Wang,et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.
[71] Zhen Gu,et al. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy , 2017, Nature Biomedical Engineering.
[72] R. Weichselbaum,et al. Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. , 2016, Journal of the American Chemical Society.
[73] Ligeng Xu,et al. Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy , 2016, Nature Communications.
[74] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[75] D. Hanahan,et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.
[76] Quanyin Hu,et al. Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. , 2018, Nano letters.
[77] Jinming Yu,et al. PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.
[78] Hao Cheng,et al. PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy , 2018, Advanced materials.
[79] Ralph R. Weichselbaum,et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.
[80] S. Quezada,et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies , 2009, The Journal of experimental medicine.
[81] H. Schneider,et al. CD28 and CTLA‐4 coreceptor expression and signal transduction , 2009, Immunological reviews.
[82] Ronnie H. Fang,et al. Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity , 2017, Advanced materials.
[83] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[84] M. Drutskaya,et al. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. , 2017, Cytokine.
[85] I. Weissman,et al. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.
[86] I. Kwon,et al. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. , 2017, ACS nano.
[87] Charles Pelizzari,et al. Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy , 2018, Nature Biomedical Engineering.
[88] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[89] Ping Yang,et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. , 2013, Clinical lung cancer.
[90] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] Tasuku Honjo,et al. Cancer immunotherapies targeting the PD-1 signaling pathway , 2017, Journal of Biomedical Science.
[92] M. Wasik,et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.
[93] Philip J. R. Goulder,et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.
[94] I. Weissman,et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity , 2017, Proceedings of the National Academy of Sciences.
[95] P. Hegde,et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.
[96] P. Scherle,et al. Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. , 2009, Current cancer drug targets.
[97] U. Grohmann,et al. The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.
[98] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[99] Quanyin Hu,et al. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. , 2016, ACS nano.
[100] Ligeng Xu,et al. Immunological Responses Triggered by Photothermal Therapy with Carbon Nanotubes in Combination with Anti‐CTLA‐4 Therapy to Inhibit Cancer Metastasis , 2014, Advanced materials.
[101] Daniel G. Anderson,et al. Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.
[102] A. Jimeno,et al. Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies , 2012, Investigational New Drugs.
[103] J. Wolchok,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[104] Jun Wang,et al. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[105] R. Weichselbaum,et al. Chlorin-Based Nanoscale Metal-Organic Framework Systemically Rejects Colorectal Cancers via Synergistic Photodynamic Therapy and Checkpoint Blockade Immunotherapy. , 2016, Journal of the American Chemical Society.
[106] Drew M. Pardoll,et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.
[107] Yichao Chen,et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy , 2016, Nature Communications.
[108] J. Drijfhout,et al. Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. , 2014, Vaccine.
[109] Conglian Yang,et al. Bone Marrow Dendritic Cells Derived Microvesicles for Combinational Immunochemotherapy against Tumor , 2017 .
[110] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[111] Y. Kienast,et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.
[112] T. Nomura,et al. CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.
[113] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[114] Ryan L. Kelly,et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.
[115] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[116] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[117] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[118] A. Ribas,et al. SnapShot: Immune Checkpoint Inhibitors. , 2017, Cancer cell.
[119] D. Peer,et al. Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target , 2008, Science.
[120] D. Hanahan,et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.
[121] J. Moon,et al. Designer vaccine nanodiscs for personalized cancer immunotherapy , 2016, Nature materials.
[122] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[123] Benjamin G. Bitler,et al. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. , 2016, Cell reports.
[124] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[125] Tsuyoshi Murata,et al. {m , 1934, ACML.
[126] A. Nel,et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression , 2017, Nature Communications.
[127] T. MacDonald,et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma , 2014, Journal of Immunotherapy for Cancer.